University of Alberta Hospital (University of Alberta)

Edmonton, Alberta T6G 2XB

6 studies enrolling now · 16 studies all time

What they study most

Atrial Fibrillation, Chronic Kidney Disease, Dermatitis, Atopic, Idiopathic Pulmonary Fibrosis, Kidney Disease, Chronic, Leukemia, Myeloid, Acute, Liver Cirrhosis, Myocardial Infarction, Progressive Pulmonary Fibrosis, Psychotic Disorders, Pulmonary Disease, Chronic Obstructive, Pulmonary Emphysema

Studies at this site

• A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids) — Recruiting now
• A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast — Recruiting now
• A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis — Recruiting now
• A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH) — Recruiting now
• A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum — Recruiting now
• EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) — Recruiting now
• A Study in Patients With Atopic Eczema to Test How Effective BI 655130 is and How Well it is Tolerated — Completed
• A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) — Completed
• This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year — Stopped early
• EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction) — Completed
• Longitudinal Follow up to Assess Biomarkers Predictive of Emphysema Progression in Patients With COPD (Chronic Obstructive Pulmonary Disease) — Completed
• Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2) — Completed
• GLORIA-AF Registry Program - Second and Third Phases — Completed
• Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS) — Completed
• Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment — Completed
• Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF) — Completed